| Health / Medical Topics |
HLA-A*2402-restricted Multipeptide Vaccine S-488410
A cancer vaccine composed of HLA-*2402-restricted epitopic peptides derived from three cancer/testis (CT) antigens, with potential antineoplastic activity. Upon subcutaneous administration, HLA-A*2402-restricted multipeptide vaccine S-488410 may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these CT antigens. CT antigens, normally expressed only in germ cells of the testis, are overexpressed in a wide variety of human cancers. (NCI Thesaurus)
YOU MAY ALSO LIKE
A cancer vaccine containing five HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from…
A cancer vaccine containing five HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from…
A cancer vaccine containing two HLA-A*2402-restricted peptide epitopes derived from cancer-testis antigens with potential immunostimulatory and antitumor activities. The peptide epitopes are…
A cancer vaccine containing the HLA-A*2402-restricted peptide epitope derived from cell division associated gene 1 (CDCA1), with potential immunostimulatory and antitumor…
A cancer vaccine containing two HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from:…
A cancer vaccine containing an HLA-A*0201-restricted vascular endothelial growth factor receptor 1 (VEGFR1) peptide (sequence: TLFWLLLTL) with potential immunostimulatory and antitumor…
